Skip to main content

Table 1 Clinical and pathological characteristics of breast cancer patients

From: The prognostic significance of RUNX2 and miR-10a/10b and their inter-relationship in breast cancer

Characteristicsa

N (%)

Age (mean ± SD and range)

59.2 ± 13.2 (35–102 yrs)

Gender

 

  Male

1 (0.9%)

  Female

107 (99.1%)

Histology

 

  Ductal

95 (88.0%)

  Other

13 (12.0%)

Grade

 

  I

7 (6.6%)

  II

36 (34.0%)

  III

63 (59.4%)

Stage

 

  0

3 (2.8%)

  I

34 (31.8%)

  II

46 (43.0%)

  III

24 (22.4%)

ER

 

  Negative

48 (44.4%)

  Positive

60 (55.6%)

PR

 

  Negative

40 (37.0%)

  Positive

68 (63.0%)

Her2

 

  Negative

53 (49.1%)

  Positive

55 (50.9%)

Molecular subtype

 

  Luminal A

36 (33.3%)

  Luminal B

38 (35.3%)

  ER-, PR-, Her2+

17 (15.7%)

  ER-, PR-, Her2-

17 (15.7%)

Regional lymph node involvement

 

  No

62 (58.5%)

  Yes

44 (41.5%)

Relapse

 

  No

71 (65.7%)

  Yes

37 (34.3%)

RFS duration median (range)

54.6 (1.1 ~ 100.9 months)

Outcomes

 

  Alive

100 (92.5%)

  Dead

8 (7.5%)

OS duration median (range)

63.2 (1.6 ~ 217.9 months)

  1. ER: estrogen receptor, PR: progesterone receptor, HER2: HER2/neu, RFS: relapse free survival, OS: overall survival.
  2. Status of ER and PR was classified as “Positive” when 10% of cells were stained; HER2 status was defined as “Positive” when Dako score was 2+ or 3 + .
  3. aClinical characteristics according to the sixth edition of the AJCC Cancer Staging Manual (2006).